Pancreatic lipase inhibition activity of trilactone terpenes of Ginkgo biloba

References

• Arbeeny, C.M. Addressing the unmet medical need for safe and effective weight loss therapies. Obes. Res. 2004, 12, 1191–1196.
   PubMedGoogle Scholar
• Harrold, J., Williams, G., Wong, S. Neuroendocrine targets for the treatment of obesity: physiological roles and unrealized opportunities. Curr Med Chem 2003, 3, 141–155.
   Google Scholar
• Wang, Y., Beydoun, M.A., Liang, L., Caballero, B., Kumanyika, S.K. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008, 16, 2323–2330.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Beydoun, M.A. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol. Rev. 2007, 29, 6–28.
   PubMed Web of Science ®Google Scholar
• Hirani, V. Anthropometric measures, overweight and obesity. In: Sproston, K., Primatesta, P. (eds). Health Survey for England 2003. Volume 2: Risk Factors for Cardiovascular Disease. Joint Health Surveys Unit: London, 2004, pp. 143–179.
   Google Scholar
• Cameron, A.J., Welborn, T.A., Zimmet, P.Z., Dunstan, D.W., Owen, N., Salmon, J., Dalton, M., Jolley, D., Shaw, J.E. Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med. J. Aust.s 2003, 178, 427–432.
   PubMed Web of Science ®Google Scholar
• Bogers, R.P., Bemelmans, W.J., Hoogenveen, R.T., Boshuizen, H.C., Woodward, M., Knekt, P., van Dam, R.M., Hu, F.B., Visscher, T.L., Menotti, A., Thorpe, R.J., Jr., Jamrozik, K., Calling, S., Strand,  B.H., Shipley, M.J.; for the BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch. Intern. Med. 2007, 167, 1720–1728.
   PubMed Web of Science ®Google Scholar
• National task force on the prevention and treatment of obesity. Overweight, obesity, and health risk. Arch. Intern. Med. 2000, 160, 898–904.
   PubMed Web of Science ®Google Scholar
• Hyde, R. Europe battles with obesity. Lancet 2008, 371, 2160–2161.
   PubMedGoogle Scholar
• National Heart Lung and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The evidence report, 1998.
   Google Scholar
• Ballinger, A., Peikin, S.R. Orlistat: its current status as an anti-obesity drug. Eur. J. Pharmacol. 2002, 440, 109–117.
   PubMed Web of Science ®Google Scholar
• Yanovski, S.Z., Yanovski, J.A. Obesity. N. Engl. J. Med. 2002, 346, 591–602.
   PubMed Web of Science ®Google Scholar
• Winkler, F.K., D’Arcy, A., Hunziker, W. Structure of human pancreatic lipase. Nature 1990, 343, 771–774.
   PubMed Web of Science ®Google Scholar
• Tilbeurgh, H.V. Structure of the pancreatic lipase–procolipase complex. Nature 1992, 359, 159–162.
   PubMed Web of Science ®Google Scholar
• Gargouri, Y., Ransac, S., Verger, R. Covalent inhibition of digestive lipases: an in vitro study. Biochim. Biophys. Acta 1997, 1344, 6–37.
   PubMed Web of Science ®Google Scholar
• Hadváry, P., Lengsfeld, H., Wolfer, H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 1988, 256, 357–361.
   PubMed Web of Science ®Google Scholar
• Drent, M.L., van der Veen, E.A. Lipase inhibition: a novel concept in the treatment of obesity. Int. J. Obes. Relat. Metab. Disord. 1993, 17, 241–244.
   PubMed Web of Science ®Google Scholar
• Bustanji, Y., Mohammad, M., Hudaib, M., Tawaha, K., Al-Masri, I., AlKhatib, H., Issa, A., Alali, F. Screening of some medicinal plants for their pancreatic lipase inhibitory potential. Jordan J. Pharm. Sci. 2010, Jordan J. Pharm. Sci. In Press.
   Google Scholar
• Morikawa, T., Xie, Y., Asao, Y., Okamoto, M., Yamashita, C., Muraoka, O., Matsuda, H., Pongpiriyadacha, Y., Yuan, D., Yoshikawa, M. Oleanane-type triterpene oligoglycosides with pancreatic lipase inhibitory activity from the pericarps of Sapindus rarak. Phytochemistry 2009, 70, 1166–1172.
   PubMedGoogle Scholar
• Nakai, M., Fukui, Y., Asami, S., Toyoda-Ono, Y., Iwashita, T., Shibata, H., Mitsunaga, T., Hashimoto, F., Kiso, Y. Inhibitory effects of oolong tea polyphenols on pancreatic lipase in vitro. J. Agric. Food Chem. 2005, 53, 4593–4598.
   PubMed Web of Science ®Google Scholar
• Tian, W.X., Li, L.C., Wu, X.D., Chen, C.C. Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase. Life Sci. 2004, 74, 2389–2399.
   PubMed Web of Science ®Google Scholar
• Cheng, J., Ni, H., Guo, W., Yu, L., Shen, Q., Lin, Y. Chinese medicinal composition effective in reducing blood glucose and blood lipid, and its preparation method and uses. Faming Zhuanli Shenqing Gongkai Shuomingshu 2007, CODEN: CNXXEV CN 101085121 A 20071212. Application: CN 2007-10024578 20070622.
   Google Scholar
• Dubey, A.K., Devi, A., Kutty, G., Shankar, R.P. Hypolipidemic activity of Ginkgo biloba extract, EGB 761 in hypercholesterolemic wistar rats. Iran J. Pharmacol. Ther. 2005, 4, 9–12.
   Google Scholar
• Christen, Y. Use of Ginkgo biloba extract for increasing muscle mass and reducing fat mass. Faming Zhuanli Shenqing Gongkai Shuomingshu 2005, CODEN: CNXXEV CN 1668321 A 20050914. Application: CN 2003-816570 20030715.
   Google Scholar
• Duan, Z., Guo, S., He, D., Yan, X. Traditional Chinese medicine extract capable of inhibiting lipase activity. Faming Zhuanli Shenqing Gongkai Shuomingshu 2009, 24 pp. CODEN: CNXXEV CN 101361886 A 20090211 Application: CN 2007-10120014 20070807.
   Google Scholar
• Mahady, G.B. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J. Cardiovasc. Nurs. 2002, 16, 21–32.
   PubMedGoogle Scholar
• Yao, P., Song, F., Li, K., Zhou, S., Liu, S., Sun, X., Nussler, A.K., Liu,  L. Ginkgo biloba extract prevents ethanol induced dyslipidemia. Am. J. Chin. Med. 2007, 35, 643–652.
   PubMedGoogle Scholar
• Singh, B., Kaur, P., Gopichand, Singh, R.D., Ahuja, P.S. Biology and chemistry of Ginkgo biloba. Fitoterapia 2008, 79, 401–418.
   PubMed Web of Science ®Google Scholar
• Chen, J.W., Chen, Y.H., Lin, F.Y., Chen, Y.L., Lin, S.J. Ginkgo biloba extract inhibits tumor necrosis factor-alpha-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1559–1566.
   PubMed Web of Science ®Google Scholar
• Kudolo, G.B., Wang, W., Barrientos, J., Elrod, R., Blodgett, J. The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers. J. Herb. Pharmacother. 2004, 4, 13–26.
   PubMedGoogle Scholar
• Koltermann, A., Hartkorn, A., Koch, E., Fürst, R., Vollmar, A.M., Zahler, S. Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in vivo. Cell. Mol. Life Sci. 2007, 64, 1715–1722.
   PubMed Web of Science ®Google Scholar
• Yao, Z.X., Han, Z., Drieu, K., Papadopoulos, V. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J. Nutr. Biochem. 2004, 15, 749–756.
   PubMedGoogle Scholar
• Maitra, I., Marcocci, L., Droy-Lefaix, M.T., Packer, L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem. Pharmacol. 1995, 49, 1649–1655.
   PubMed Web of Science ®Google Scholar
• Cho, H.J., Nam, K.S. Inhibitory effect of ginkgolide B on platelet aggregation in a cAMP- and cGMP-dependent manner by activated MMP-9. J. Biochem. Mol. Biol. 2007, 40, 678–683.
   PubMedGoogle Scholar
• OMEGA (version 2.3.2) 2008. OpenEye Scientific Software Inc., Santa Fe, New Mexico, USA.
   Google Scholar
• FRED (version 2.2.5) 2009. OpenEye Scientific Software, (www.eyesopen.com), USA.
   Google Scholar
• Egloff, M.P., Marguet, F., Buono, G., Verger, R., Cambillau, C., van Tilbeurgh, H. The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. Biochemistry 1995, 34, 2751–2762.
   PubMed Web of Science ®Google Scholar
• Lee, Y.P., Chung, G.H., Rhee, J.S. Purification and characterization of Pseudomonas fluorescens SIK W1 lipase expressed in Escherichia coli. Biochim. Biophys. Acta, Lipids Lipid Metab. 1993, 1169, 156–164.
   PubMed Web of Science ®Google Scholar
• Sharma, N., Sharma, V.K., Seo, S.Y. Screening of some medicinal plants for anti-lipase activity. J. Ethnopharmacol. 2005, 97, 453–456.
   PubMed Web of Science ®Google Scholar
• Mohammad, M., Aiedeh, K.M., Alkhatib, H.S., Tawaha,  K., Alkhalidi,  B., Al-Masri, I.M., Hamed, S., Bustanji, Y.A. Comparative enzymatic inhibition assay as a surrogate indicator of pharmaceutical and potency equivalence of two orlistat formulations. Jordan J. Pharm. Sci. 2010, 3, 69–75.
   Google Scholar
• Ding, Z. Studies on extraction and isolation of flavonoids from ginkgo leaves. J. Food Quality 1999, 22, 693–700.
   Google Scholar
• Bustanji, Y., Taha, M.O., Almasri, I.M., Al-Ghussein, M.A., Mohammad, M.K., Alkhatib, H.S. Inhibition of glycogen synthase kinase by curcumin: investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J. Enzyme Inhib. Med. Chem. 2009, 24, 771–778.
   PubMed Web of Science ®Google Scholar